touchIMMUNOLOGY were delighted to speak with Prof. Maarten Boers (Amsterdam University Medical Center, Amsterdam, The Netherlands) to discuss the GLORIA trial, investigating the benefits and harms of long term add-on low dose prednisolone in rheumatoid arthritis.
The abstract ‘Favorable balance of benefit and harm of long-term, low dose prednisolone added to standard treatment in rheumatoid arthritis patients aged 65+: The pragmatic, multicenter, placebo- controlled GLORIA trial.’ (Abstract number: OP0263) was presented at the European Congress of Rheumatology 2022, 1-4 June, 2022.
Questions
- What is known about the benefits and harms of long term, low dose glucocorticoid therapy in rheumatoid arthritis (RA), and what questions remain unanswered? (0:18)
- What were the objectives and methodology of the GLORIA trial? (1:22)
- What were the findings of the study in terms of benefits and harms? (1:57)
- What were the conclusions of the investigators regarding future use of add-on low dose prednisolone in RA? (4:14)
- Which patients are most likely to benefit from this approach and in whom is it contraindicated? (5:52)
Disclosures: Maarten Boers discloses consulting for Novartis.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the EULAR meeting 2022.
